Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Imclone systems (IMCL) -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (520)	3/26/1999 12:29:00 PM
From: StockMiser	Read Replies (2) \| Respond to of 2515

Actually, Imclone is involved in 8 presentations at the upcoming AACR annual conference: VE-cadherin specific monoclonal antibody inhibits angiogenesis and tumor growth in vivo. janis.expocity.com Oxygen levels during antivascular, neoplastic and combined therapy. janis.expocity.com Regression of human pancreatic carcinoma growing orthotopically in athymic nude mice by blockade of epidermal growth factor receptor (EGF-R) signaling in combination with Gemcitabine. janis.expocity.com Second wave of angiogenesis during KDR/flk-1 antibody therapy. janis.expocity.com Growth inhibition of human pancreatic carcinoma in vitro janis.expocity.com Treatment of human intracranial gliomas with chimeric monoclonal antibody against the epidermal growth factor receptor increases survival of nude mice when treated concurrently with irradiation. janis.expocity.com Effect of anti-VEGF receptor monoclonal antibodies on tumor growth and angiogenesis in SCID mouse/human skin graft model. janis.expocity.com VEGF receptor blockade by an anti-Flk1 monoclonal antibody inhibits tumor associated angiogenesis and tumor growth. janis.expocity.com And contrary to what someone said, these conferences are often used to formally present data that has not been seen before. So, most of these probably are, to some degree, new findings. This is certainly the case with MGI Pharma (MOGN), also scheduled to present new data. I gotta say something about the shorts. Currently, I'm not long or short IMCL (I was long at 9 1/2, but sold recently). Most of the shorts have NEVER, in their entire trading careers, dealt with a biotech company in final phase III trials of a novel cancer treatment, and they are making a HUGE mistake by applying "normal" biotech "pump/dump" strategies to it. At least 2 trading boards predicted sub-12 within 2 days of the run-up...but it hasn't happened. Listen, this isn't some ENMD with pre-clinical studies and less than 20% chance of ultimate success in 5-7 years. This is a company getting major exposure and insitutional investing. When analysts give a $14 stock a 36 month potential of $60-100, it's going to gather lots of support. The stock is showing a LOT of buying during any dips. Shorts can say all day that final approval is still not certain....but the chances of success at this point, with this treatment, for this disease, under this FDA climate, is at least 80% imho. Shorts and longs both realize it, and thats why the stock just can't seem to stay below 14 - on weakness, shorts cover and longs buy. The media attention of a late stage trial like this won't disappear either...we will see more of it. Holding an IMCL short is like holding a gun to your temple waiting for the next click. SM